Interventions for erythema nodosum leprosum

A Systematic Review on the Epidemiological Data of Erythema Nodosum Leprosum, a Type 2 Leprosy Reaction

“…65 papers met the inclusion criteria. Four literature reviews were analysed separately [2], [12], [15], [16]. One relevant workshop report was included [17].…”

A Systematic Review on the Epidemiological Data of Erythema Nodosum Leprosum, a Type 2 Leprosy Reaction

“…65 papers met the inclusion criteria. Four literature reviews were analysed separately [2], [12], [15], [16]. One relevant workshop report was included [17].…”

Erythema Nodosum Leprosum in a Patient with Borderline Lepromatous Leprosy: A Case Report

“…Our patient’s condition necessitated high-dose corticosteroids with transition to thalidomide as an outpatient, which remain a mainstay of treatment for severe ENL. Methotrexate was introduced to proactively manage type 1 reaction, as recommended by the Hansen Center [ 7 , 8 ].…”

“…Clofazimine is classified as an investigational drug and is not used for acute type 2 reactions (TR2) but may be used for chronic TR2 in patients unable to take thalidomide or high-dose steroids [ 10 ]. Regular follow-up with a specialized leprosy center is crucial for monitoring treatment response and detecting potential complications [ 2 , 8 ].…”

Case report: Cyclophosphamide pulse therapy for chronic recalcitrant erythema nodosum leprosum

“…Leprosy remains a burden in more than 120 countries and is considered by the WHO to be the most common infectious cause of disability in the world (13). Nevertheless, the incredible negligence toward the disease is reflected in the very few alternatives and trials for the development of new drugs that are more effective and safer for managing reactions (14).…”

A Systematic Review on the Epidemiological Data of Erythema Nodosum Leprosum, a Type 2 Leprosy Reaction

“…65 papers met the inclusion criteria. Four literature reviews were analysed separately [2], [12], [15], [16]. One relevant workshop report was included [17].…”

Erythema Nodosum Leprosum in a Patient with Borderline Lepromatous Leprosy: A Case Report

“…Our patient’s condition necessitated high-dose corticosteroids with transition to thalidomide as an outpatient, which remain a mainstay of treatment for severe ENL. Methotrexate was introduced to proactively manage type 1 reaction, as recommended by the Hansen Center [ 7 , 8 ].…”

“…Clofazimine is classified as an investigational drug and is not used for acute type 2 reactions (TR2) but may be used for chronic TR2 in patients unable to take thalidomide or high-dose steroids [ 10 ]. Regular follow-up with a specialized leprosy center is crucial for monitoring treatment response and detecting potential complications [ 2 , 8 ].…”

Case report: Cyclophosphamide pulse therapy for chronic recalcitrant erythema nodosum leprosum

“…Leprosy remains a burden in more than 120 countries and is considered by the WHO to be the most common infectious cause of disability in the world (13). Nevertheless, the incredible negligence toward the disease is reflected in the very few alternatives and trials for the development of new drugs that are more effective and safer for managing reactions (14).…”

A Systematic Review on the Epidemiological Data of Erythema Nodosum Leprosum, a Type 2 Leprosy Reaction

“…65 papers met the inclusion criteria. Four literature reviews were analysed separately [2], [12], [15], [16]. One relevant workshop report was included [17].…”

Erythema Nodosum Leprosum in a Patient with Borderline Lepromatous Leprosy: A Case Report

“…Our patient’s condition necessitated high-dose corticosteroids with transition to thalidomide as an outpatient, which remain a mainstay of treatment for severe ENL. Methotrexate was introduced to proactively manage type 1 reaction, as recommended by the Hansen Center [ 7 , 8 ].…”

“…Clofazimine is classified as an investigational drug and is not used for acute type 2 reactions (TR2) but may be used for chronic TR2 in patients unable to take thalidomide or high-dose steroids [ 10 ]. Regular follow-up with a specialized leprosy center is crucial for monitoring treatment response and detecting potential complications [ 2 , 8 ].…”

Case report: Cyclophosphamide pulse therapy for chronic recalcitrant erythema nodosum leprosum

“…Leprosy remains a burden in more than 120 countries and is considered by the WHO to be the most common infectious cause of disability in the world (13). Nevertheless, the incredible negligence toward the disease is reflected in the very few alternatives and trials for the development of new drugs that are more effective and safer for managing reactions (14).…”